meChANisms and sAfety of SGLT2 Inhibition in peRitoneal dialYsis

Abroad (travel likely)RecruitingPHASE3

Conditions

Peritoneal Dialysis Complication · End Stage Kidney Disease · Sodium-glucose Co-transporter-2 Inhibitors · Kidney Dysfunction · Residual Kidney Function

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Toronto General Hospital, Toronto, Ontario, Canada
Contact: Study coordinator (Vesta Lai) · vesta.lai@uhn.ca · 416-340-4800

Study leads

Sunita KS Singh, MD MSc FRCPC
Principal Investigator
University Health Network, Toronto General Hospital

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Blood Pressure Control With Thiazide Diuretics in Peritoneal Dialysis Patients

Hypertension · Peritoneal Dialysis · End Stage Kidney Disease (ESRD)

Abroad (travel likely)RecruitingPHASE4

Hong Kong, Hong Kong

Empagliflozin on Residual Kidney Function in Incident Peritoneal Dialysis Patients

End Stage Renal Disease on Dialysis · Peritoneal Dialysis Complication · Sodium-glucose Cotransporter-2 Inhibitor

Abroad (travel likely)RecruitingPHASE2

Hong Kong, Hong Kong

Dapagliflozin Delays the Loss of Renal Function in Peritoneal Dialysis Patients

Peritoneal Dialysis Complication · Renal Function Aggravated · Sodium-glucose Co-transporter-2 Inhibitors

Abroad (travel likely)Recruiting

Chengdu, China

International (Pediatric) Peritoneal Biobank

Kidney Failure, Chronic · Peritoneal Dialysis Complication · Transplantation

Abroad (travel likely)Recruiting

Birmingham, United States · Kansas City, United States